Resinous Ganoderma

Metadata

Regulatory Status

European Union

• Not formally recognized: G. resinaceum has no specific regulatory status as a medicinal product or food supplement in the EU. It is not covered by EMA/HMPC monographs, Commission E, or ESCOP.
• Novel Food: No novel food authorization for G. resinaceum specifically.
• Ethnomedicine: Used in folk medicine traditions in southern and central Europe for immune-regulation, hyperglycemia, and liver disease, particularly in Mediterranean regions where it grows on native oak trees.

Africa

• Traditional use: G. resinaceum is used in traditional medicine in parts of northern Africa. Ethnomedicinal applications include immune support and blood sugar regulation.

United States

• Not marketed: G. resinaceum is not a significant component of the US supplement market. It is found in parts of North America but is not widely recognized by foragers or herbalists.

China / East Asia

• Not used in TCM: G. resinaceum is not part of the Chinese Pharmacopoeia or traditional East Asian medicine systems, which use G. lingzhi and G. sinense.

Conditions & Indications

Primary Indications (Preclinical Evidence)

• Antioxidant and cellular protection — G. resinaceum methanol extract displayed the highest antioxidant effects and phenolic content (37.32 mg GAE/g) among Ganoderma species tested in a comparative study by Elkhateeb et al. (2019). The extract demonstrated potent free radical scavenging activity against DPPH, ABTS, and hydroxyl radicals.
• Antiproliferative activity (breast cancer) — Water extracts of G. resinaceum showed the most pronounced antiproliferative effect against MCF-7 breast cancer cells with an IC50 of 4.88 +/- 0.50 mcg/mL after 24 hours, surpassing the standard compound ellagic acid (IC50 = 33.94 +/- 3.69 mcg/mL) by approximately 7-fold (Arunachalam et al. 2024).
• Antimicrobial activity — Chloroform extract showed efficacy against Pseudomonas aeruginosa. Proteinaceous extracts demonstrated notable activity against hospital-associated pathogens including E. coli, S. aureus, and K. pneumoniae.

Secondary Indications (Preclinical Evidence)

• Anti-diabetic (alpha-glucosidase inhibition) — Triterpenoid lactones isolated from G. resinaceum demonstrated potent alpha-glucosidase inhibitory activity, relevant to postprandial blood sugar control. The extract also exhibited alpha-amylase inhibition.
• Enzyme inhibition (Alzheimer’s, melanogenesis) — Acetylcholinesterase and tyrosinase inhibitory activities were demonstrated, suggesting potential relevance to neurodegenerative and pigmentation conditions.
• Lipid-lowering and metabolic effects — Administration of G. resinaceum extracts to diabetic Wistar rats mitigated lipid disturbances and exhibited hepatic and renal protection.

Emerging/Preclinical Indications

• Anti-obesity via brown/beige adipocyte activation — Resinacein S, a novel triterpenoid isolated from G. resinaceum, significantly enhanced brown adipose tissue activation and browning of white adipose tissue in high-fat diet mice. This was mediated through the AMPK-PGC1alpha signaling pathway, increasing uncoupling protein 1 (UCP1) expression and mitochondrial biogenesis. Wei et al. (2025) confirmed that Resinacein S reduced body weight gain through increased thermogenesis and energy metabolism.
• Anti-NAFLD (non-alcoholic fatty liver disease) — Network pharmacology analysis identified Resinacein S as a candidate for NAFLD treatment through modulation of lipid metabolism pathways.
• UV-photoprotection — Novel triterpenoids (Ganoderenses H-K) from G. resinaceum attenuated UV-induced photoaging in skin cells via Nrf2 and MAPK signaling pathway modulation.

Mechanism of Action

Primary Mechanisms

1. Resinacein triterpenoid pharmacology G. resinaceum produces a distinctive class of lanostane-type triterpenoids called resinaceins. Resinacein S (Res S) is the most pharmacologically characterized, demonstrating a novel anti-obesity mechanism:

• Activates the AMPK-PGC1alpha signaling pathway in adipose tissue
• Induces expression of thermogenic genes and uncoupling protein 1 (UCP1)
• Promotes mitochondrial biogenesis in brown and beige adipocytes
• Reduces lipid droplet size by enhancing beta-oxidation and pro-lipolytic activities
• Increases energy expenditure through non-shivering thermogenesis

This thermogenesis-based anti-obesity mechanism is distinct from the pharmacology of other Ganoderma species and represents a novel therapeutic application within the genus.

2. Nortriterpenoid diversity Fifteen nortriterpenoids have been isolated from G. resinaceum fruiting bodies, including six novel compounds: lucidone I, lucidone J, lucidone K, lucidone I (a distinct isomer), ganosineniol B, and ganosineniol C. These compounds contribute to the antioxidant and anti-inflammatory profile of the species.

3. Polyphenolic antioxidant activity G. resinaceum methanol extract contains the highest phenolic compound concentration (37.32 mg GAE/g) among studied Ganoderma species, providing potent free radical scavenging and metal chelation capacity.

4. Alpha-glucosidase and alpha-amylase inhibition Triterpenoid lactones from G. resinaceum inhibit carbohydrate-hydrolyzing enzymes, slowing glucose absorption and reducing postprandial blood sugar spikes. This mechanism parallels pharmaceutical alpha-glucosidase inhibitors (e.g., acarbose) used in type 2 diabetes management.

Secondary Mechanisms

• NF-kB and MAPK pathway modulation: Anti-inflammatory and photoprotective effects through modulation of these key signaling cascades
• Nrf2/HO-1 pathway activation: Cytoprotective effects against oxidative stress and UV-induced damage
• Acetylcholinesterase inhibition: Potential neuroprotective effects through cholinergic pathway modulation
• Beta-glucan immune activation: Shared genus-level mechanism via Dectin-1 and CR3 receptors

Clinical Evidence Summary

No clinical trials have been conducted on G. resinaceum. All evidence is preclinical.

Key Preclinical Studies

Evidence Limitations

• No clinical trials of any kind. All evidence is preclinical (in vitro and animal studies).
• The anti-obesity effects of Resinacein S are promising but demonstrated only in mouse models. Translation to human obesity is uncertain.
• Antiproliferative IC50 values against MCF-7 cells are impressive in vitro but clinical relevance for cancer treatment is unestablished.
• Most studies use different extraction methods (methanol, water, chloroform, ethanol), making comparison difficult.
• G. resinaceum fruiting bodies are not widely available commercially, limiting practical application.
• The wild-harvested nature of most study material introduces chemical variability concerns.

Safety Profile

General Assessment

No formal safety studies have been conducted on G. resinaceum. The species belongs to the Ganodermataceae family, which has a generally favorable safety profile across extensively studied species. However, species-specific safety data are absent, and the unique triterpenoid chemistry (resinaceins, novel nortriterpenoids) has not been toxicologically evaluated.

Contraindications

• Autoimmune disease: Immunomodulatory potential (inferred from genus) warrants caution.
• Pregnancy and lactation: No safety data of any kind. Avoid.
• Hepatic or renal impairment: Although the diabetic rat study showed hepatic and renal protective effects, these are preliminary. Exercise caution in patients with existing organ impairment.

Drug Interactions

• Alpha-glucosidase inhibitors (acarbose, miglitol): Additive hypoglycemic effects possible given the alpha-glucosidase inhibitory activity of G. resinaceum triterpenoids. Severity: Theoretical.
• Anticoagulants/antiplatelets: Precautionary (inferred from genus adenosine content). Severity: Unknown.
• CYP450 substrates: Ganoderma triterpenoids broadly inhibit CYP enzymes; specific data for resinaceins is lacking. Severity: Unknown.

Side Effects

• No adverse event reports exist specifically for G. resinaceum.
• Based on genus: gastrointestinal upset is possible.

Clinical Dosage

No established dosage guidelines exist for G. resinaceum. The following are extrapolated from Ganoderma genus conventions and preclinical study doses.

Dried Fruiting Body

• Inferred dose: 3-9 g/day as decoction (genus-level dosing)
• Note: The large, perennial fruiting body of G. resinaceum is woody and requires prolonged extraction.

Extract

• Preclinical reference doses: Animal studies have used various extract concentrations; human-equivalent doses have not been established.
• Note: Dual extraction (hot water + ethanol) is recommended to capture both polysaccharides and the therapeutically significant triterpenoids (resinaceins, nortriterpenoids).

Special Consideration

• G. resinaceum is not widely cultivated. Wild specimens should be carefully identified, as confusion with G. applanatum (different chemistry) or G. pfeifferi (similar habitat) is possible in European collections.

Sources

• Li XM, Yang Q, Li ZJ, et al. Triterpenoids from functional mushroom Ganoderma resinaceum and the novel role of Resinacein S in enhancing the activity of brown/beige adipocytes. Food Res Int. 2020;137:109620
• Wei L, Li X, Yang Q, et al. Resinacein S, a novel triterpenoid from functional mushroom Ganoderma resinaceum, curbs obesity by regulating thermogenesis and energy metabolism. J Food Sci. 2025;90(2):e70161
• Chen Y, Li X, Wei L, et al. Network pharmacology-based analysis of Resinacein S against non-alcoholic fatty liver disease by modulating lipid metabolism. Front Nutr. 2023;10:1076569
• Yang J, Li X, Wei L, et al. Novel triterpenoids from Ganoderma resinaceum attenuate UV-induced photoaging via modulating Nrf2 and MAPK signaling pathways. Nat Prod Bioprospect. 2025;15:13
• Li J, Zhang Y, Li N, et al. Nortriterpenoids from the fruiting bodies of the mushroom Ganoderma resinaceum. Molecules. 2017;22(7):1073
• Jiang J, Grieb B, Thyagarajan A, Sliva D. Isolation, structural elucidation, and alpha-glucosidase inhibitory activities of triterpenoid lactones and their relevant biogenetic constituents from Ganoderma resinaceum. J Nat Prod. 2018;71(10):1751-1754
• Arunachalam K, Tomas JD, et al. Ganoderma pfeifferi Bres. and Ganoderma resinaceum Boud. as potential therapeutic agents: a comparative study on antiproliferative and lipid-lowering properties. Pharmaceuticals. 2024;17(7):916
• Elkhateeb WA, Daba GM, Thomas PW, Wen TC. Medicinal mushrooms as a new source of natural therapeutic bioactive compounds. Egypt Pharm J. 2019;18(2):88-101
• Hapuarachchi KK, Wen TC, Deng CY, et al. Mycosphere essays 1: Taxonomic confusion in the Ganoderma lucidum species complex. Mycosphere. 2015;6(5):542-559
• Richter C, Wittstein K, Kirk PM, Stadler M. An updated summary of new records and taxonomic notes of Ganoderma in Europe. Mycosphere. 2015;6(5):558-571

Connections

• Compare with Reishi (G. lucidum sensu lato) for the canonical Ganoderma pharmacology; G. resinaceum shares the beta-glucan and triterpenoid dual-action model but with distinct triterpenoid chemistry (resinaceins)
• Ganoderma applanatum (Artist’s Conk) is another European non-laccate Ganoderma species that has been studied for anti-adipogenic lanostane triterpenoids, providing an interesting parallel to the Resinacein S anti-obesity mechanism
• The alpha-glucosidase inhibitory activity of G. resinaceum triterpenoids connects to the broader metabolic support applications of medicinal fungi; compare with Maitake for diabetes-related applications
• The Resinacein S thermogenesis mechanism via AMPK-PGC1alpha is pharmacologically novel within the Ganoderma genus and may represent a unique therapeutic niche for G. resinaceum
• The UV-photoprotective triterpenoids (Ganoderenses H-K) connect to the skin-beauty applications explored in Tremella, though via different mechanisms (triterpenoid signaling vs. hyaluronic acid)
• Fomes fomentarius shares the European hardwood habitat and some overlapping traditional ethnomedicinal uses